The team at RetroSense Therapeutics, seasoned veterans with experience taking medical technology from the discovery stage to the clinic, knew 2016 could be a breakout year for the company. RetroSense’s therapy, based on research conducted at Wayne State University in Detroit, was almost ready for its biggest test yet: a Phase I/II clinical trial. In […]
An investment made by several groups of early-stage Michigan investors could pay off in a big way following the recent news that Allergan acquired Ann Arbor-based RetroSense Therapeutics LLC, a Michigan angel-backed gene therapy company, for $60 million plus additional funding if the company reaches future milestones. Terry Cross, MVCA member, and director of RetroSense […]
Angel investors might invest in one of every 100 opportunities that come before them—long odds for a startup, for sure. Ann Arbor-based RetroSense Therapeutics, a privately-held biopharmaceutical company, had already beat those odds, having raised $7 million in a 2014 angel-led Series A financing round that included Midland’s Blue Water Angels Investment Network. But the […]